Coverage
-
September 21, 2018
Compounder Athenex Pharma Solutions LLC is wrongly attempting to broaden a U.S. Food and Drug Administration policy governing bulk compounding, and its "gross misinterpretation" must be kept out of Par Pharmaceutical's suit challenging that policy, an AmerisourceBergen Corp. subsidiary has told a D.C. federal court.
6 other articles on this case.
View all »